A Drug–Antibody Conjugate Improves Survival in HER2-Positive, Metastatic Breast Cancer
Trastuzumab emtansine (T-DM1) is a unique molecule that uses trastuzumab as a backbone to target human epidermal growth factor receptor 2 (HER2)-positive breast cancer and utilizes a stable linker to deliver emtansine, an extremely potent cytotoxic agent that, if administered as monotherapy, has prohibitive toxicity.
Now, Blackwell and colleagues report results of the randomized, phase III EMILIA study [Abstract LBA1], which compared the effectiveness and safety of T-DM1 versus combination capecitabine and lapatinib (CL) in 991 patients with HER2-positive breast cancer previously treated with a taxane and trastuzumab. Patients were eligible if they had prog…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)